Rivastigmine Capsules in Patients With Probable Vascular Dementia

An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00130338

Enrollment

521

Registered

2005-08-15

Start date

2002-02-28

Completion date

2006-05-31

Last updated

2017-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular Dementia

Keywords

Dementia, Vascular, Rivastigmine, Stroke, Memory loss

Brief summary

The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

Interventions

DRUGRivastigmine

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Patients who complete the double-blind treatment phase or those who have dropped out early in the study, but have returned for all the remaining scheduled efficacy assessments (retrieved drop-out patients) without significant protocol violations are eligible to participate.

Exclusion criteria

* Retrieved drop-out patients, who have been treated with other cholinergic drugs during the past 4 weeks

Design outcomes

Primary

Measure	Time frame
Safety and tolerability of rivastigmine for up to 52 weeks of treatment in patients with VaD and probable VaD	—

Secondary

Measure	Time frame
52 week's treatment with rivastigmine on cognition, activities of daily living, behavior and clinical staging in patients with VaD and probable VaD	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026